Business
Arecor granted key patents in Europe and China
Arecor granted key patents in Europe and China.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n\nArecor Therapeutics plc\n(\"Arecor\" or the \"Group\")\n \nARECOR GRANTED KEY PATENTS IN EUROPE AND CHINA TO PROTECT PROPRIETARY INSULIN PRODUCTS\n \nPatents further strengthen Group's extensive patent portfolio protecting its Arestat™ technology and innovative insulin products, AT278 and AT247\n \nCambridge, UK, 27 June 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, is pleased to announce that the European Patent Office has granted a key patent (EP3518892), protecting novel formulations of the Group's proprietary insulin products, AT278 and AT247. In addition, the China National Intellectual Property Administration has granted a further patent (CN110582285) protecting AT278 and AT247.\n \nDr Jan Jezek, Chief Scientific Officer at Arecor, commented: \"Our innovative Arestat™ enabled insulin products, AT278 and AT247, have the potential to address key needs in the better treatment of diabetes. AT278 is a 'disrupter insulin', a unique formulation which combines an ultra-rapid profile and high concentration and has potential as the gold standard insulin for the growing population of people with high daily insulin needs, as well as a key enabler for pump miniaturisation and extended wear-time. AT247 has a 'best-in-class' ultra-rapid pharmacokinetic profile with the potential to enable fully automated insulin delivery systems. Diabetes is one of the leading causes of death and disability worldwide, and affects people regardless of country, age group, or sex. These additional granted patents aim to serve and protect Arecor's innovative technologies in these important markets.\"\n \nArecor has invested in a strong patent portfolio to protect the Arestat™ technology platform and its proprietary pipeline products. The Group's intellectual property (IP) portfolio currently comprises 36 patent families, including >75 granted patents in Europe, the US and in other key territories, and provides protection for its key products. As part of this strategy, Arecor has robust IP that protects the novel compositions of AT278 and AT247 as well as their specific properties and methods of use until 2037.\n \nAT278 is an ultra-concentrated (500 U/mL) novel formulation of insulin that has been designed to accelerate the absorpt...